Single-Arm, Phase II Proof of Concept Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2018
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 May 2018 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.